1
|
Gerra MC, González-Villar A, Arendt-Nielsen L, Søkilde Pedersen I, Triñanes Y, Donnini C, Manfredini M, Walther D, Moeller GL, Pidal-Miranda M, Romero-Yuste S, Arias-Gómez M, Carrillo-de-la-Peña MT. A family-based study to identify genetic biomarkers of fibromyalgia: consideration of patients' subgroups. Clin Exp Rheumatol 2021; 39 Suppl 130:144-152. [PMID: 34161225 DOI: 10.55563/clinexprheumatol/bq7x9n] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2021] [Accepted: 05/20/2021] [Indexed: 11/13/2022]
Abstract
OBJECTIVES Evidence from genome-wide and candidate gene association studies, familial aggregation and linkage analyses demonstrate the genetic contribution to fibromyalgia (FM) disease. This study aimed to identify genetic biomarkers of FM and its related comorbid disorders, by exploring 41 polymorphisms potentially involved in FM pathogenesis in families with at least one patient with FM. METHODS Core symptoms were assessed, and blood samples collected from 556 patients with FM and 395 healthy relatives. For the genetic study, a final sample of 401 FM patients and 232 healthy controls was selected, discarding patients with concomitant pathologies and controls with chronic pain. A family-based approach using DFAM test (Plink) and SNPs (single nucleotide polymorphisms) combination analyses to compare FM patients vs. controls were first applied. Second, the genotypic distribution of subgroups of FM patients, stratified by severe vs. mild symptoms of pain, depression and sleep impairment, was considered. RESULTS No evidence of associations with FM per se were detected, using either a family-based approach or SNPs combination analyses. However, considering the subgroups of FM patients, the SNP rs6454674 (CNR1, cannabinoid receptor 1 gene) was found as a potential genetic marker of FM correlated with depression (p<.001). CONCLUSIONS No significant associations using either the family-based analysis or the SNPs combination tests dissociated FM patients and their healthy relatives. FM patients with and without depression showed a significant difference in the genotypic distribution related to the SNP rs6454674 in the cannabinoid receptor 1 gene (CNR1) indicating that FM is not a homogenous disorder.
Collapse
Affiliation(s)
- Maria Carla Gerra
- Centre for Neuroplasticity and Pain (CNAP), SMI®, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark.
| | - Alberto González-Villar
- Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Spain
| | - Lars Arendt-Nielsen
- Centre for Neuroplasticity and Pain (CNAP), SMI®, Department of Health Science and Technology, Aalborg University, Aalborg, Denmark
| | - Inge Søkilde Pedersen
- Aalborg University Hospital and Aalborg University, Molecular Diagnostics and Department of Clinical Medicine, Aalborg, Denmark
| | - Yolanda Triñanes
- Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Spain
| | - Claudia Donnini
- Department of Chemistry, Life Sciences, and Environmental Sustainability, University of Parma, Italy
| | - Matteo Manfredini
- Department of Chemistry, Life Sciences, and Environmental Sustainability, University of Parma, Italy
| | - Donna Walther
- Designer Drug Research Unit, Intramural Research Program of the National Institute on Drug Abuse, National Institutes of Health, Baltimore, MD, USA
| | - Gert Lykke Moeller
- Genokey ApS, ScionDTU, Technical University of Denmark, Hoersholm, Denmark
| | - Marina Pidal-Miranda
- Department of Clinical Psychology and Psychobiology, University of Santiago de Compostela, Spain
| | | | - Manuel Arias-Gómez
- Neurology Service, University Complex Hospital of Santiago de Compostela, Spain
| | | |
Collapse
|
2
|
Mellerup E, Andreassen OA, Bennike B, Dam H, Djurovic S, Jorgensen MB, Kessing LV, Koefoed P, Melle I, Mors O, Moeller GL. Combinations of genetic variants associated with bipolar disorder. PLoS One 2017; 12:e0189739. [PMID: 29267373 PMCID: PMC5739413 DOI: 10.1371/journal.pone.0189739] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/09/2017] [Accepted: 11/30/2017] [Indexed: 12/02/2022] Open
Abstract
The main objective of the study was to find genetic variants that in combination are significantly associated with bipolar disorder. In previous studies of bipolar disorder, combinations of three and four single nucleotide polymorphisms (SNP) genotypes taken from 803 SNPs were analyzed, and five clusters of combinations were found to be significantly associated with bipolar disorder. In the present study, combinations of ten SNP genotypes taken from the same 803 SNPs were analyzed, and one cluster of combinations was found to be significantly associated with bipolar disorder. Combinations from the new cluster and from the five previous clusters were identified in the genomes of 266 or 44% of the 607 patients in the study whereas none of the 1355 control participants had any of these combinations in their genome.The SNP genotypes in the smaller combinations were the normal homozygote, heterozygote or variant homozygote. In the combinations containing 10 SNP genotypes almost all the genotypes were the normal homozygote. Such a finding may indicate that accumulation in the genome of combinations containing few SNP genotypes may be a risk factor for bipolar disorder when those combinations contain relatively many rare SNP genotypes, whereas combinations need to contain many SNP genotypes to be a risk factor when most of the SNP genotypes are the normal homozygote.
Collapse
Affiliation(s)
- Erling Mellerup
- Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
- * E-mail:
| | - Ole A. Andreassen
- Department of Psychiatry, Oslo University Hospital and Institute of Psychiatry, University of Oslo, Oslo, Norway
| | - Bente Bennike
- Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
| | - Henrik Dam
- Psychiatric Centre Copenhagen, Department O, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Srdjan Djurovic
- Department of Medical Genetics, Oslo University Hospital and Institute of Psychiatry, University of Oslo, Oslo, Norway
| | - Martin Balslev Jorgensen
- Psychiatric Centre Copenhagen, Department O, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Lars Vedel Kessing
- Psychiatric Centre Copenhagen, Department O, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark
| | - Pernille Koefoed
- Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Copenhagen, Denmark
| | - Ingrid Melle
- Department of Psychiatry, Oslo University Hospital and Institute of Psychiatry, University of Oslo, Oslo, Norway
| | - Ole Mors
- Centre for Psyciatric Research, Aarhus University Hospital, Skovagervej 2, Risskov, Denmark
| | - Gert Lykke Moeller
- Genokey ApS, ScionDTU, Technical University Denmark, Agern Allé 3, Hoersholm, Denmark
| |
Collapse
|
3
|
Abstract
In the single locus strategy a number of genetic variants are analyzed, in order to find variants that are distributed significantly different between controls and patients. A supplementary strategy is to analyze combinations of genetic variants. A combination that is the genetic basis for a polygenic disorder will not occur in in control persons genetically unrelated to patients, so the strategy is to analyze combinations of genetic variants present exclusively in patients. In a previous study of oral cancer and leukoplakia 325 SNPs were analyzed. This study has been supplemented with an analysis of combinations of two SNP genotypes from among the 325 SNPs. Two clusters of combinations containing 95 patient specific combinations were significantly associated with oral cancer or leukoplakia. Of 373 patients with oral cancer 205 patients had a number of these 95 combinations in their genome, whereas none of 535 control persons had any of these combinations in their genome.
Collapse
Affiliation(s)
- Erling Mellerup
- Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, Faculty of Health, University of Copenhagen, Denmark
| | - Gert Lykke Moeller
- Genokey ApS, ScionDTU, Technical University of Denmark, Hoersholm, Denmark
| | | | - Susanta Roychoudhury
- Cancer Biology and Inflammatory Disorder Division, CSIR-Indian Institute of Chemical Biology, Kolkata, India
| |
Collapse
|
4
|
Mellerup E, Andreassen OA, Bennike B, Dam H, Djurovic S, Hansen T, Jorgensen MB, Kessing LV, Koefoed P, Melle I, Mors O, Werge T, Moeller GL. Combinations of Genetic Data Present in Bipolar Patients, but Absent in Control Persons. PLoS One 2015; 10:e0143432. [PMID: 26587987 PMCID: PMC4654514 DOI: 10.1371/journal.pone.0143432] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/02/2015] [Accepted: 11/04/2015] [Indexed: 11/19/2022] Open
Abstract
The main objective of the study was to find combinations of genetic variants significantly associated with bipolar disorder. In a previous study of bipolar disorder, combinations of three single nucleotide polymorphism (SNP) genotypes taken from 803 SNPs were analyzed, and four clusters of combinations were found to be significantly associated with bipolar disorder. In the present study, combinations of four SNP genotypes taken from the same 803 SNPs were analyzed, and one cluster of combinations was found to be significantly associated with bipolar disorder. Combinations from the new cluster and from the four previous clusters were identified in the genomes of 209 of the 607 patients in the study whereas none of the 1355 control participants had any of these combinations in their genome.
Collapse
Affiliation(s)
- Erling Mellerup
- Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 9 O-6102, DK-2100 Copenhagen, Denmark
- * E-mail:
| | - Ole A. Andreassen
- Department of Psychiatry, Oslo University Hospital and Institute of Psychiatry, University of Oslo, Kirkeveien 166. 0407 Oslo, Norway
| | - Bente Bennike
- Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 9 O-6102, DK-2100 Copenhagen, Denmark
| | - Henrik Dam
- Psychiatric Centre Copenhagen, Department O, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9 O-6102, DK-2100 Copenhagen, Denmark
| | - Srdjan Djurovic
- Department of Medical Genetics, Oslo University Hospital and Institute of Psychiatry, University of Oslo, Kirkeveien 166. 0407 Oslo, Norway
| | - Thomas Hansen
- Department of Biological Psychiatry, Mental Health Centre Sct. Hans, Copenhagen University Hospital, Boserupvej 2, DK-4000 Roskilde, Denmark
| | - Martin Balslev Jorgensen
- Psychiatric Centre Copenhagen, Department O, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9 O-6102, DK-2100 Copenhagen, Denmark
| | - Lars Vedel Kessing
- Psychiatric Centre Copenhagen, Department O, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9 O-6102, DK-2100 Copenhagen, Denmark
| | - Pernille Koefoed
- Laboratory of Neuropsychiatry, Department of Neuroscience and Pharmacology, University of Copenhagen, Blegdamsvej 9 O-6102, DK-2100 Copenhagen, Denmark
- Psychiatric Centre Copenhagen, Department O, Copenhagen University Hospital, Rigshospitalet, Blegdamsvej 9 O-6102, DK-2100 Copenhagen, Denmark
| | - Ingrid Melle
- Department of Psychiatry, Oslo University Hospital and Institute of Psychiatry, University of Oslo, Kirkeveien 166. 0407 Oslo, Norway
| | - Ole Mors
- Centre for Psyciatric Research, Aarhus University Hospital, Skovagervej 2, DK-8240 Risskov, Denmark
| | - Thomas Werge
- Department of Biological Psychiatry, Mental Health Centre Sct. Hans, Copenhagen University Hospital, Boserupvej 2, DK-4000 Roskilde, Denmark
| | - Gert Lykke Moeller
- Genokey ApS, ScionDTU, Technical University Denmark, Agern Allé 3, DK-2970 Hoersholm, Denmark
| |
Collapse
|
5
|
Abstract
The Venture Evaluation and Review Technique (VERT) is a computerized, mathematically oriented network-based simulation technique designed to analyze risk existing in three parameters of most concern to managers in new projects or ventures--time, cost, and performance. As such, the VERT technique is more powerful than techniques such as GERT, which are basically time and cost oriented. VERT has been successfully utilized to assess the risks involved in new ventures and projects, in the estimation of future capital requirements, in control monitoring, and in the overall evaluation of ongoing projects, programs, and systems. It has been helpful to management in cases where there is a requirement to make decisions with incomplete or inadequate information about the alternatives. An example describing the application of VERT to an operational planning problem--the evaluation of electric power generating methods--is illustrated.
Collapse
|